Cargando…
Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
Oncolytic peptides represent a novel, promising cancer treatment strategy with activity in a broad spectrum of cancer entities, including colorectal cancer (CRC). Cancer cells are killed by immunogenic cell death, causing long-lasting anticancer immune responses, a feature of particular interest in...
Autores principales: | Fleten, Karianne Giller, Eksteen, J. Johannes, Mauseth, Brynjar, Camilio, Ketil André, Vasskog, Terje, Sveinbjørnsson, Baldur, Rekdal, Øystein, Mælandsmo, Gunhild M., Flatmark, Kjersti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991660/ https://www.ncbi.nlm.nih.gov/pubmed/33762676 http://dx.doi.org/10.1038/s41598-021-86239-6 |
Ejemplares similares
-
Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals
por: Zhou, Heng, et al.
Publicado: (2018) -
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
por: Camilio, Ketil A., et al.
Publicado: (2019) -
The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma
por: Eike, Liv-Marie, et al.
Publicado: (2016) -
The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma
por: Mauseth, Brynjar, et al.
Publicado: (2019) -
LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
por: Camilio, Ketil André, et al.
Publicado: (2014)